|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 330.00 CHF | -1.55% |
|
-8.03% | +0.55% |
| 11/03 | Regenxbio's Duchenne gene therapy shows improved muscle function in trial | RE |
| 11/03 | AlphaValue/Baader Europe Upgrades Roche to Add Rating, Trims PT | MT |
| Capitalization | 26TCr 34TCr 29TCr 25TCr 46TCr 31,17300Cr 47TCr 3,11700Cr 1,24300Cr 14,90500Cr 1,26800Cr 1,24200Cr 53,68800Cr | P/E ratio 2026 * |
17.8x | P/E ratio 2027 * | 16.5x |
|---|---|---|---|---|---|
| Enterprise value | 27TCr 35TCr 30TCr 26TCr 47TCr 32,14400Cr 49TCr 3,21400Cr 1,28100Cr 15,36900Cr 1,30800Cr 1,28000Cr 55,36000Cr | EV / Sales 2026 * |
4.33x | EV / Sales 2027 * | 4.08x |
| Free-Float |
87.84% | Yield 2026 * |
3.05% | Yield 2027 * | 3.13% |
Last Transcript: Roche Holding AG
| 1 day | -1.55% | ||
| 1 week | -8.03% | ||
| Current month | -10.08% | ||
| 1 month | -7.51% | ||
| 3 months | +3.81% | ||
| 6 months | +22.95% | ||
| Current year | +0.55% |
| 1 week | 315.6 |  | 346.5 |
| 1 month | 315.6 | | 374.9 |
| Current year | 315.6 | | 374.9 |
| 1 year | 231.9 | | 374.9 |
| 3 years | 212.9 | | 374.9 |
| 5 years | 212.9 | | 404.2 |
| 10 years | 206.35 | | 404.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 51 | 15/03/2023 | |
Alan Hippe
DFI | Director of Finance/CFO | 59 | 06/06/2011 |
Wafaa Mamilli
CTO | Chief Tech/Sci/R&D Officer | 59 | 10/02/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
André Hoffmann
BRD | Director/Board Member | 67 | 01/01/1996 |
Severin Schwan
CHM | Chairman | 59 | 15/03/2023 |
| Director/Board Member | 73 | 03/03/2015 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -.--% | 9.03% | 121 M€ | |
| -2.67% | 8.46% | 26 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.55% | -8.03% | +11.30% | +25.17% | 35TCr | |
| -0.15% | -0.37% | +21.33% | +217.39% | 89TCr | |
| -0.30% | -0.94% | +46.50% | +60.27% | 59TCr | |
| +0.30% | -3.60% | +6.60% | +52.08% | 40TCr | |
| -1.16% | -4.00% | +26.17% | +35.39% | 31TCr | |
| -0.62% | -5.04% | +26.69% | +62.48% | 30TCr | |
| -0.75% | -3.38% | +22.67% | +7.91% | 29TCr | |
| +0.59% | -0.43% | +18.42% | +65.73% | 20TCr | |
| -1.72% | -1.50% | +27.59% | +83.65% | 18TCr | |
| +1.15% | +1.77% | -52.91% | -50.02% | 17TCr | |
| Average | -0.18% | -1.67% | +15.44% | +56.00% | 36.81TCr | |
| Weighted average by Cap. | +0.10% | -1.84% | +20.45% | +84.61% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 6.28TCr 8.05TCr 6.96TCr 6.01TCr 11TCr 7,42800Cr 11TCr 74TCr 30TCr 3,55200Cr 30TCr 30TCr 12,79300Cr | 6.5TCr 8.34TCr 7.2TCr 6.22TCr 11TCr 7,68700Cr 12TCr 77TCr 31TCr 3,67500Cr 31TCr 31TCr 13,23800Cr |
| Net income | 1.45TCr 1.86TCr 1.61TCr 1.39TCr 2.53TCr 1,71400Cr 2.6TCr 17TCr 6.83TCr 82TCr 6.97TCr 6.83TCr 2,95100Cr | 1.56TCr 2TCr 1.72TCr 1.49TCr 2.71TCr 1,84000Cr 2.79TCr 18TCr 7.33TCr 88TCr 7.49TCr 7.33TCr 3,16900Cr |
| Net Debt | 821.18Cr 1.05TCr 909.58Cr 785.35Cr 1.43TCr 97TCr 1.47TCr 9.71TCr 3.87TCr 46TCr 3.95TCr 3.87TCr 1,67200Cr | 128.9Cr 165.23Cr 142.77Cr 123.27Cr 224.7Cr 15TCr 231.02Cr 1.52TCr 607.36Cr 7.29TCr 619.97Cr 606.92Cr 26TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/26/11 | 330.00 CHF | -1.55% | 14,31,167 |
| 10/26/10 | 335.20 CHF | +0.84% | 12,33,077 |
| 09/26/09 | 332.40 CHF | -2.58% | 22,66,833 |
| 06/26/06 | 341.20 CHF | -2.93% | 13,39,562 |
| 05/26/05 | 351.50 CHF | -2.03% | 10,87,503 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ROG Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition